Measuring therapeutic oligonucleotides in biological matrices: a review of hybridization assay formats
With the emergence of novel chemical modifications, antisense oligonucleotide therapies have been developed over the last two decades and are now in clinical trials that focus on a multitude of indications.
This class of molecules presents promising avenues to be explored with tailored n=1 medicines that target specific mutations at a personalized level. A bioanalytical tool that can provide fast turnaround is paramount to developing these therapies. Hybridization-based assays are enzyme-linked immunosorbent assays (ELISA) routinely used to measure oligonucleotide drug therapies. This assay platform can be easily established by designing complementary probes to the drug of interest.
In this presentation, you will hear about the various assay formats available and the key considerations for selecting a bioanalytical platform for specific oligonucleotide therapies.
What will you learn?
- Gain insight into the hybridization ELISA methodology used in the measurement of gene therapies
- The key features of oligonucleotide therapeutics and considerations during bioanalytical method development
- The various hybridization assay formats available for establishing the pharmacokinetics of a drug post-dose
- Advantages and limitations of the main bioanalytical platforms LC-MS and hybridization ELISA
Who may this interest?
- Pharma/Biotech companies working on antisense oligonucleotides and siRNA development
- Pharma/Biotech companies interested in the preclinical and clinical bioanalysis of therapeutic oligonucleotides
- Individuals interested in quantitative bioanalytical techniques by hybridization ELISA
- Individuals studying the toxicokinetics and pharmacokinetics of oligonucleotide-drug therapies
Speaker
Helen Legakis
Principal Scientist
Charles River Laboratories (QC, Canada)
Helen Legakis, Principal Scientist, oversees the oligonucleotide hybridization ELISA services within the Immunochemistry department at Charles River’s site in Montreal, Canada. She received her BSc in Biochemistry at McGill University (Montreal, Canada) in 2003 and throughout her graduate studies, she applied various immunobiological methods to determine the intracellular signaling pathway of a G-protein-coupled receptor linked to obesity.
In 2005, Helen completed her MSc in Biochemistry at McGill University and joined Charles River that same year where she was involved in developing, validating and coordinating bioanalytical drug programs for several pharmaceutical and biotechnology sectors in support of regulatory preclinical and clinical studies. Helen works on various drug programs that include siRNA and antisense oligonucleotides, focusing on establishing hybridization methods for the quantitation of these oligonucleotides in various biological fluids and tissues.
This webinar was recorded on Tuesday 6 June 2023.
In association with
